Status:
COMPLETED
Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma
Lead Sponsor:
Groupe Oncologie Radiotherapie Tete et Cou
Collaborating Sponsors:
Sanofi
Conditions:
Larynx Cancer
Hypopharynx Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to compare two regimen of chemotherapy used as first treatment for patients with larynx or hypopharynx tumors that would be treated with total laryngectomy. The standard tr...
Detailed Description
The purpose of the study is to compare two regimen of induction chemotherapy for patients with T3 and T4 larynx or hypopharynx carcinoma that would be treated with total laryngectomy. The aim of the s...
Eligibility Criteria
Inclusion
- T3 and T4 larynx and hypopharynx tumor that would be treated with total laryngectomy
- Biopsy proven carcinoma
- Adequate biology
- Performance status 0 or 1
Exclusion
- Larynx or hypopharynx tumors that could be treated with partial laryngectomy
- Distant metastasis
- Prior surgery, chemotherapy or radiation
- Intercurrent disease that is a contra indication to chemotherapy
Key Trial Info
Start Date :
December 15 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00169182
Start Date
December 15 2001
End Date
May 1 2009
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Bretonneau
Tours, France, 37044